RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.
Diabet Med
; 25(8): 889-94, 2008 Aug.
Article
em En
| MEDLINE
| ID: mdl-18959599
ABSTRACT
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic beta-cells. Agents that either mimic GLP-1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance endogenous GLP-1 release are under assessment. As intestinal peptides have a range of actions, including appetite regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug development.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polipeptídeo Inibidor Gástrico
/
Diabetes Mellitus Tipo 2
/
Células Secretoras de Insulina
/
Peptídeo 1 Semelhante ao Glucagon
/
Incretinas
/
Insulina
Limite:
Humans
Idioma:
En
Revista:
Diabet Med
Assunto da revista:
ENDOCRINOLOGIA
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Reino Unido